Meeting
2023 ASCO Annual Meeting
Predicting absolute benefit in risk of metastasis of androgen deprivation therapy added to radiation therapy in patients with newly diagnosed prostate cancer using Prolaris.
Authors
Jonathan David Tward
Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT
Jonathan David Tward , Lauren Lenz , Alexander Gutin , Wyatt Clegg , Rob Finch , Todd Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5030)
DOI
10.1200/JCO.2023.41.16_suppl.5030
Abstract #
5030
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim
Poster
2023 ASCO Annual Meeting
Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT.
First Author: Ye Yuan
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz